1945 Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status. (September 2015) - Jackisch, C.; Hegg, R.; Stroyakovskiy, D.; Ahn, J.S.; Melichar, B.; Chen, S.C.; Crepelle-Fléchais, A.; Lauer, S.; Shing, M.; Pivot, X.